New test detects Parkinson’s biomarker before movement symptoms start

Fierce Biotech, April 18, 2023

A new test could make it possible to diagnose Parkinson’s disease before symptoms appear, paving the way for early intervention.

According to the results of a nearly decadelong study published April 12 in The Lancet Neurology, a team of scientists with the Parkinson’s Progression Markers Initiative—a longstanding biomarkers study backed by actor Michael J. Fox’s Parkinson’s research nonprofit—described how they developed an assay to detect deposits of a protein called alpha-synuclein in the cerebrospinal fluid of hundreds of at-risk and early-stage patients…READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.